Skip to content

Medical emergency? What to do

New chest pain drug set for March launch, co. says

3-RXPublished February 25, 20062 min read

Key points

  • Chief Executive Officer Louis Lange said on Thursday that the company's recently approved drug for chest pain is on track to be in 30,000 pharmacies by the end of March.
  • Lange said the company's 250-person sales force plans to begin marketing the drug at a major meeting of cardiologists next month in Atlanta and shipments will start shortly thereafter.
  • Ranexa, which directs the heart to burn sugar for energy instead of fat, works without dropping blood pressure, which is a common side effect of other angina treatments.
  • About 25 percent of the estimated 6.4 million Americans with chronic angina have become resistant to existing drugs.

CV Therapeutics Inc. Chief Executive Officer Louis Lange said on Thursday that the company's recently approved drug for chest pain is on track to be in 30,000 pharmacies by the end of March.

Palo Alto, California-based CV Therapeutics last month received U.S. Food and Drug Administration approval of Ranexa for treatment of chronic angina, the chest pain caused by an insufficient supply of oxygen to the heart.

Lange said the company's 250-person sales force plans to begin marketing the drug at a major meeting of cardiologists next month in Atlanta and shipments will start shortly thereafter.

"We expect to be in 30,000 retail outlets by the end of March," the CEO said.

Ranexa, which directs the heart to burn sugar for energy instead of fat, works without dropping blood pressure, which is a common side effect of other angina treatments.

The FDA approved Ranexa for patients who have not achieved adequate response with other anti-anginal drugs, and said it should be used in combination with other treatments, such as beta-blockers or nitrates.

About 25 percent of the estimated 6.4 million Americans with chronic angina have become resistant to existing drugs.

The new drug option "is going to be a big deal for patients and their doctors," Lange said "Patients will know very quickly if this is working and how well."

The company is conducting another trial of Ranexa in patients with acute coronary syndrome (ACS), which occurs when a plaque inside an artery ruptures and blocks blood flow to the heart muscle.

This trial, results from which are expected late this year or early next year, provides "two ways for CV Therapeutics to win," Lange explained.

Ranexa's approval in chronic angina had been delayed for years over safety concerns, including indications that it prolonged the "QT interval" - the time it takes the heart to electrically recharge itself.

Safety data from the ACS trial may put those concerns to rest, opening the way to expanding Ranexa's label to include first-line treatment of all patients with chronic angina, the CEO said.

In addition, if the trial's primary goal is met, CV Therapeutics would be able for file with the FDA for approval of Ranexa as a treatment for ACS, which affects 1.2 million Americans.

"This drug has got a lot of value embedded in it. It represents a strategic change in the way cardiac patients will be treated," Lange said.

The content on this site is for information only and is not a substitute for professional medical advice, diagnosis or treatment. Drug information pages are an archive and may be out of date: always follow your prescriber, your pharmacist and the current product label. In an emergency, call 911.

Filed underDrug News

Keep reading

Cancer

Experimental drug shrinks cancer tumors

An experimental cancer drug successfully shrank tumors in patients with different kinds of cancer, including typically hard-to-treat lung cancers, according to a new study. Oncologists said the research was…

4 min read

Cancer

Avastin Slows Resistant Ovarian Cancer

Progression of platinum-resistant ovarian cancer slowed by more than 50% in patients who received bevacizumab (Avastin) plus chemotherapy compared with nonplatinum chemotherapy alone, results of a randomized trial…

3 min read

Drug News

Prevnar trial results needed for CDC recommendation

Advisors to the U.S. Centers for Disease Control and Prevention on Wednesday will wait for results from a trial of Pfizer Inc's Prevnar 13 pneumonia vaccine before deciding whether to recommend its use in all adults…

1 min read

When to get help

Reading is for later. These need care now.

Call 911 or go to an emergency department if you or someone with you has any of these:

  • Chest pain or pressureEspecially with breathlessness, sweating or pain in the arm, jaw or back. It can be a heart attack.
  • Face drooping, arm weakness, slurred speechSigns of a stroke. Note the time they started: treatment works best within hours.
  • Severe trouble breathingIncluding a severe allergic reaction with swelling of the lips, tongue or throat.
  • Thoughts of suicideCall or text 988 (Suicide & Crisis Lifeline, US) any time, day or night.

Outside the US, call your local emergency number.

See a doctor within days

  1. 01A new lump, or a sore that does not healMost lumps are harmless, but anything that grows or lasts more than a few weeks should be checked.
  2. 02Unexplained weight loss or lasting fatigueLosing weight without trying, or tiredness that does not lift, can have many causes worth finding.
  3. 03A new medicine and new symptomsSide effects and interactions are common. Ask your pharmacist or prescriber before you stop anything.

General guidance only. If you are unsure how urgent a symptom is, call your doctor or a nurse advice line.